Atrial fibrillation (AFib)


Atrial Fibrillation Predicts Longer Length of Stay Among Coronary Bypass Patients in Nevada

No Image

By: James Pitt  May. 15, 2018

Atrial fibrillation (AF) is a type of heart arrhythmia common in patients over 40. A 2016 study in Journal of Internal Medicine found that “the estimated lifetime risk of developing AF is one in four for men and women aged 40 years and above. Projected data from multiple population-based studies in the USA and Europe predict a two- to threefold increase in the number of AF patients by 2060.” Dexur has previously examined how AF affects readmission rates in patients with comorbid respiratory conditions.

Read more

Eliquis Has Potential in Impacting Readmission Rates of Pulmonology Patients with Atrial Fibrillation

No Image

By: Saparja Nag  Apr. 26, 2018

Eliquis (apixaban) is primarily prescribed to patients with nonvalvular atrial fibrillation to reduce risk of stroke, as well as to prevent deep vein thrombosis or pulmonary embolisms. Although AFib can occur for a number of different reasons, AFib and reduced pulmonary function are often comorbid. One study from 2009 offered three explanations for the relationship between these two conditions, given below.

Read more

Eliquis Could Impact In-Hospital Mortality Rates of Renal Failure Patients with Atrial Fibrillation

No Image

By: Saparja Nag  Apr. 17, 2018

Eliquis, an oral anticoagulant developed by Bristol-Myers Squibb, is targeted at reducing patients’ risk of stroke or systemic embolism in patients with non-valvular atrial fibrillation, in addition to preventing and treating DVT (deep vein thrombosis) and PE (pulmonary embolism) in high-risk patients. The link between atrial fibrillation and conditions of the kidney has been examined in numerous clinical studies but the exact impact of anticoagulants on renal failure patients’ risk of bleeding has yet to be empirically understood in clinical trials.

Read more